Wynne CJ - Search Results

1

Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males.

Wynne CJ, Ellis-Pegler RB, Waaka DS, Schwabe C, Lehle M, Heinzmann D, Mangat R, Li C, Dick AE, Cranshaw NA, Lum BL. Wynne CJ, et al. Cancer Chemother Pharmacol. 2013 Nov;72(5):1079-87. doi: 10.1007/s00280-013-2273-z. Epub 2013 Sep 22. Cancer Chemother Pharmacol. 2013. PMID: 24057039 Clinical Trial.

2

Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer.

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Wynne C, et al. J Clin Pharmacol. 2013 Feb;53(2):192-201. doi: 10.1177/0091270012436560. J Clin Pharmacol. 2013. PMID: 23436264 Clinical Trial.

3

Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer.

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Wynne C, et al. J Clin Pharmacol. 2013 Jan 24. doi: 10.1177/0091270011436560. Online ahead of print. J Clin Pharmacol. 2013. PMID: 23504807

4

Reply to: letter to the editor "subcutaneous herceptin therapy".

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Wynne C, et al. J Clin Pharmacol. 2013 Dec;53(12):1343-4. doi: 10.1002/jcph.172. Epub 2013 Sep 21. J Clin Pharmacol. 2013. PMID: 23996383 No abstract available.

5

A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin^® (EU and US) in healthy male subjects.

Wynne C, Schwabe C, Batra SS, Lopez-Lazaro L, Kankanwadi S. Wynne C, et al. Br J Clin Pharmacol. 2018 Oct;84(10):2352-2364. doi: 10.1111/bcp.13691. Epub 2018 Jul 26. Br J Clin Pharmacol. 2018. PMID: 29943831 Free PMC article. Clinical Trial.

6

Bioavailability of Orally Administered Active Lipid Compounds from four Different Greenshell™ Mussel Formats.

Miller MR, Kruger MC, Wynne C, Waaka D, Li W, Frampton C, Wolber FM, Eason C. Miller MR, et al. Mar Drugs. 2020 Oct 23;18(11):524. doi: 10.3390/md18110524. Mar Drugs. 2020. PMID: 33114125 Free PMC article. Clinical Trial.

7

Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.

Wynne C, Altendorfer M, Sonderegger I, Gheyle L, Ellis-Pegler R, Buschke S, Lang B, Assudani D, Athalye S, Czeloth N. Wynne C, et al. Expert Opin Investig Drugs. 2016 Dec;25(12):1361-1370. doi: 10.1080/13543784.2016.1255724. Expert Opin Investig Drugs. 2016. PMID: 27813422 Clinical Trial.

8

Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.

Schwabe C, Illes A, Ullmann M, Ghori V, Vincent E, Petit-Frere C, Monnet J, Racault AS, Wynne C. Schwabe C, et al. Expert Rev Clin Immunol. 2022 May;18(5):533-543. doi: 10.1080/1744666X.2022.2060204. Epub 2022 Apr 10. Expert Rev Clin Immunol. 2022. PMID: 35354411 Clinical Trial.

9

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta^® in healthy subjects: A randomized, double-blind trial.

Wynne C, Schwabe C, Vincent E, Schueler A, Ryding J, Ullmann M, Ghori V, Kanceva R, Stahl M. Wynne C, et al. Pharmacol Res Perspect. 2020 Apr;8(2):e00578. doi: 10.1002/prp2.578. Pharmacol Res Perspect. 2020. PMID: 32333641 Free PMC article. Clinical Trial.

10

A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adults.

Wynne C, Schwabe C, Stroissnig H, Dias R, Sobierska J, Guenzi E, Otto H, Sattar A, Haliduola HN, Edwald E, Berti F. Wynne C, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):773-780. doi: 10.1080/14712598.2022.2131391. Epub 2022 Oct 5. Expert Opin Biol Ther. 2023. PMID: 36197309

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

75 results

Search Page